HIV Prevention Shot Lenacapavir: Aspen Warns of Demand Risks

Original Article by Tamar Kahn | Business Day | 16 March 2026

Learn about the HIV prevention shot lenacapavir and why Aspen Pharmacare emphasises guaranteed demand for local production.

Learn about the HIV prevention shot lenacapavir and why Aspen Pharmacare emphasises guaranteed demand for local production.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

Acute Pain in African Hospitals Affects Two-Thirds of Patients

Acute pain in African hospitals affects two-thirds of patients – what the burden means for hospital groups and medical schemes.

Read more...

Mpox Cases in SA Rise as Local Transmission Accelerates

Mpox cases in South Africa are rising, mainly in the Western Cape. What the surge means for the healthcare industry.

Read more...

NHLS Scrambles as Pathology Services Funding Runs Dry

The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt

Read more...